The Ebola vaccine is one of the 20 most important scientific advances of the last decade, according to an article published by National Geographic. Two University of Florida researchers, Dr. Ira Longini and Dr. Natalie Dean, played a key role in the vaccine’s trial design and analysis.
Both biostatisticians in the University of Florida College of Public Health and Health Professions and the UF College of Medicine, Dr. Longini and Dr. Dean collaborated with an international team and the World Health Organization on a randomized trial for the vaccine, known as rVSV-ZEBOV-GP, during the Guinea outbreak in 2015. The team used a ring vaccination approach to test the new vaccine.
In findings published in the journal Lancet in 2016, the researchers reported that the vaccine is nearly 100 percent effective at preventing Ebola when given 10 or more days before exposure.
The European Commission, the executive branch of the European Union, approved rVSV-ZEBOV-GP for licensing last month.Tags: Friday Letter Submission, Publish on December 27